OYE Therapeutics Receives FDA Clearance to Begin Clinical Testing of Novel Caffeine Injection for Anesthesia Recovery
Key Insights
OYE Therapeutics (search) received FDA clearance for its Investigational New Drug application for OYE-101, a novel intravenous caffeine formulation designed to reverse general anesthesia (search) and deep sedation (search) effects.
The company completed a $5 million convertible note financing round to support Phase 1 clinical trials and subsequent pivotal studies for the first-in-class therapy.
OYE-101 addresses critical unmet medical needs in perioperative recovery and emergency care, with potential applications for opioid-induced respiratory depression (search) including fentanyl overdose.
OYE Therapeutics (search) announced that the U.S. Food and Drug Administration has cleared its Investigational New Drug application for OYE-101, a novel intravenous caffeine formulation designed to reverse the effects of general anesthesia (search) and deep sedation (search) in adults. The FDA clearance authorizes the clinical-stage biopharmaceutical company to initiate clinical development of what represents the first pharmacologic agent specifically indicated to actively promote emergence from general anesthesia.
Addressing Critical Medical Gaps
Brett Dines, CEO of OYE Therapeutics (search), explained that OYE-101 is being developed for broader respiratory stimulant applications, including the treatment of opioid-induced respiratory depression (search) associated with fentanyl overdose. "There are currently no FDA-approved pharmacologic agents specifically indicated to actively promote emergence from general anesthesia (search) or to directly reverse opioid-related respiratory depression without impacting the analgesic effects of the opioid," Dines said.
The therapy targets significant clinical challenges in perioperative care. Emergence from general anesthesia (search) and deep sedation (search) can be associated with delayed awakening, residual sedation and emergence delirium (search) in the post-anesthesia care unit, contributing to patient risk, prolonged recovery and increased healthcare costs. In parallel, opioid-induced respiratory depression (search) remains a leading cause of morbidity and mortality in overdose and trauma settings, particularly with the increasing prevalence of high-potency synthetic opioids such as fentanyl.
Clinical Development Strategy
The cleared Investigational New Drug application supports a Phase 1 randomized, active- and placebo-controlled, single ascending dose clinical trial designed to evaluate the safety, tolerability and comparative pharmacokinetics of OYE-101 in healthy volunteers. Data from the study is anticipated to inform a 505(B)(2) submission for use in surgical, procedural and acute-care settings.
OYE Therapeutics (search) recently completed a $5 million convertible note financing round that was oversubscribed to $5.6 million, reflecting sustained confidence across the company's investor base. The proceeds will support the Phase 1 pharmacokinetic and safety study and subsequent pivotal trials, with the dataset leveraged across all investigational new drugs to enable an accelerated multitrack clinical program.
Military Applications and Strategic Partnerships
Beyond civilian applications, OYE Therapeutics (search) is advancing OYE-101 through a research collaboration with the U.S. Department of War (search), the Uniformed Services University of the Health Sciences and the Henry M. Jackson Foundation for the Advancement of Military Medicine (search). The collaboration focuses on evaluating the use of OYE-101 in military and battlefield-relevant medical scenarios under a sponsored, multi-year $20 million research contract.
Timeline and Future Outlook
OYE Therapeutics (search) plans to proceed with site activation and initiate enrollment in its Phase 1 study, with initial safety and pharmacokinetic data anticipated after completion of dosing. The company anticipates sharing top-line clinical results in 2026, a key milestone expected to expand engagement with strategic and financial partners across the healthcare sector.
"OYE-101 is intended to support faster, more predictable recovery and respiratory stimulation without compromising analgesia or patient safety," Dines said. "We believe OYE-101 has the potential to improve recovery profiles, enhance operational efficiency in perioperative care and provide a novel pharmacologic tool for addressing life-threatening respiratory depression."
The Indiana-based company operates from the Purdue Technology Center in the Purdue Research Park of Northwest Indiana, positioning itself as an innovative drug development company focused on improving surgical, emergency and acute-care medicine through targeted therapies.